[go: up one dir, main page]

CL2017003255A1 - Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin. - Google Patents

Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin.

Info

Publication number
CL2017003255A1
CL2017003255A1 CL2017003255A CL2017003255A CL2017003255A1 CL 2017003255 A1 CL2017003255 A1 CL 2017003255A1 CL 2017003255 A CL2017003255 A CL 2017003255A CL 2017003255 A CL2017003255 A CL 2017003255A CL 2017003255 A1 CL2017003255 A1 CL 2017003255A1
Authority
CL
Chile
Prior art keywords
antibodies
combination therapies
hematological diseases
survivin inhibitors
inhibitors
Prior art date
Application number
CL2017003255A
Other languages
English (en)
Inventor
Henk M Lokhorst
Tuna Mutis
Parul Dorshi
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CL2017003255A1 publication Critical patent/CL2017003255A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01035—Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE RELACIONA CON TERAPIAS DE COMBINACIÓN PARA ENFERMEDADES MALIGNAS HEMATOLÓGICAS CON ANTICUERPOS ANTI-CD38 E INHIBIDORES DE SURVIVINA.</p>
CL2017003255A 2015-06-22 2017-12-18 Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin. CL2017003255A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562182699P 2015-06-22 2015-06-22
US201662319036P 2016-04-06 2016-04-06

Publications (1)

Publication Number Publication Date
CL2017003255A1 true CL2017003255A1 (es) 2018-05-11

Family

ID=57585456

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017003255A CL2017003255A1 (es) 2015-06-22 2017-12-18 Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin.

Country Status (28)

Country Link
US (1) US10668149B2 (es)
EP (1) EP3310386B1 (es)
JP (1) JP6816038B2 (es)
KR (1) KR102601550B1 (es)
CN (1) CN107708734B (es)
AU (1) AU2016282674B2 (es)
BR (1) BR112017027724A2 (es)
CA (1) CA2990406A1 (es)
CL (1) CL2017003255A1 (es)
CO (1) CO2017013331A2 (es)
CR (1) CR20170587A (es)
DO (1) DOP2018000181A (es)
EA (1) EA036789B1 (es)
EC (1) ECSP17084270A (es)
ES (1) ES2890783T3 (es)
GT (1) GT201700284A (es)
IL (1) IL256242B2 (es)
MA (1) MA46315A (es)
MX (1) MX391068B (es)
MY (1) MY192978A (es)
NI (1) NI201700167A (es)
NZ (1) NZ777133A (es)
PE (1) PE20181323A1 (es)
PH (1) PH12017502342B1 (es)
SV (1) SV2017005606A (es)
UA (1) UA125115C2 (es)
WO (1) WO2016209921A1 (es)
ZA (1) ZA201800403B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA015584B1 (ru) * 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
EP3227338A4 (en) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
WO2018218633A1 (en) 2017-06-02 2018-12-06 Beijing Percans Oncology Co. Ltd. Combination therapies for treating cancers
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
WO2019195959A1 (en) 2018-04-08 2019-10-17 Cothera Biosciences, Inc. Combination therapy for cancers with braf mutation
WO2020036852A1 (en) 2018-08-13 2020-02-20 Beijing Percans Oncology Co. Ltd. Biomarkers for cancer therapy
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
CN111303293B (zh) * 2018-11-14 2022-08-30 杭州尚健生物技术有限公司 一种融合蛋白及其用途
WO2020160020A1 (en) * 2019-01-28 2020-08-06 Sanofi Methods of treating multiple myeloma
WO2021155581A1 (en) * 2020-02-07 2021-08-12 Cothera Bioscience, Inc. Combination therapies and biomarkers for treating b-cell lymphomas
CN111808193B (zh) * 2020-06-30 2022-04-05 源道隆（苏州）医学科技有限公司 可结合人cd38的纳米抗体及其应用

Family Cites Families (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
HUT53672A (en) 1988-02-25 1990-11-28 Gen Hospital Corp Quick immunoselective cloning process
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
WO1992001049A2 (en) 1990-07-13 1992-01-23 The General Hospital Corporation Cd53 cell surface antigen and use thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1994017184A1 (en) 1993-01-29 1994-08-04 Schering Corporation Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
JP4233608B2 (ja) 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
US6395276B1 (en) 1997-05-02 2002-05-28 Immunomedics, Inc. Immunotoxins directed against malignant cells
CA2269060C (en) 1996-10-17 2009-04-07 Immunomedics, Inc. Non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
WO2000006194A2 (en) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion of cells responsible for antibody-mediated graft rejection
JP2003524587A (ja) 1998-06-05 2003-08-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 多発性骨髄腫を処置するための、ｃｄ３８に対する、遺伝子操作した抗体の使用
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6838283B2 (en) 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
US7829693B2 (en) 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
CN100436425C (zh) 2000-02-15 2008-11-26 安斯泰来制药有限公司 稠合的咪唑衍生物
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CA2412901A1 (en) 2000-06-22 2001-12-27 Idec Pharmaceutical Corporation Bispecific fusion protein and method of use for enhancing effector cell killing of target cells
EP1174440A1 (en) 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
US6955884B2 (en) 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
CA2517145C (en) * 2003-03-05 2017-08-01 Halozyme, Inc. Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof
US20060223831A1 (en) 2003-04-15 2006-10-05 Isao Kinoyama Bromide and its crystal
RS20150135A1 (sr) 2003-05-30 2015-08-31 Genentech Inc. Tretman sa anti-vegf antitelima
US8597911B2 (en) 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2005042019A1 (en) 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis
DK1684805T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
JP4712724B2 (ja) 2003-12-23 2011-06-29 クルセル ホランド ベー ヴェー ＣＤ１ａに対するヒト結合分子
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
CA2555185C (en) 2004-02-06 2020-03-24 Morphosys Ag Anti-cd38 human antibodies and uses therefor
EA015584B1 (ru) 2005-03-23 2011-10-31 Генмаб А/С Антитело к cd38 человека и его применение
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
AR053489A1 (es) 2005-05-24 2007-05-09 Morphosys Ag Generacion perfilado de anticuerpos terapeuticos totalmente derivados de hucal gold humanos especificos para cd38 humano
JP5362359B2 (ja) * 2005-10-12 2013-12-11 モルフォシス アーゲー ヒトＣＤ３８に特異的な完全ヒトＨｕＣＡＬＧＯＬＤ由来の治療抗体の生成とプロファイリング
MX2008007140A (es) 2005-12-09 2009-03-04 Seattle Genetics Inc Metodos para utilizar agentes de union a cd40.
WO2007110205A2 (en) 2006-03-24 2007-10-04 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20080063642A1 (en) 2006-08-02 2008-03-13 Adelman Daniel C Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of certain hematologic disorders
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
HRP20191115T1 (hr) 2006-09-26 2019-09-20 Genmab A/S Anti-cd38 u kombinaciji s kortikosteroidima zajedno s jednim ne-kortikosteroidnim kemoterapeutikom za liječenje tumora
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
US7618992B2 (en) 2006-12-29 2009-11-17 Astellas Pharma Inc. Method of treating cancer by co-administration of anticancer agents
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
EP2162152A2 (en) 2007-06-01 2010-03-17 Biogen Idec MA, Inc. Cripto binding molecules
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
WO2009044793A1 (ja) 2007-10-02 2009-04-09 Alphagen Co., Ltd. 癌遺伝子を標的とするsiRNA
JP5559695B2 (ja) 2007-11-09 2014-07-23 ノバルティス アーゲー 抗ｃｄ４０抗体の使用
EP2237798A2 (en) 2007-12-12 2010-10-13 Imperial Innovations Limited Methods
ES2564523T3 (es) 2007-12-19 2016-03-23 Janssen Biotech, Inc. Diseño y generación de bibliotecas de presentación en fago por pIX de novo humanas mediante fusión con pIX o pVII, vectores, anticuerpos y métodos
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
JP2011517320A (ja) 2008-03-03 2011-06-02 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質およびメタロプロテアーゼ２結合タンパク質
WO2009114476A1 (en) 2008-03-12 2009-09-17 Intradigm Corporation Compositions comprising survivin sirna and methods of use thereof
ES2592312T3 (es) 2008-03-25 2016-11-29 Roche Glycart Ag Utilización de un anticuerpo anti-CD20 de tipo II con citotoxicidad celular dependiente de anticuerpos (ADCC) incrementada en combinación con ciclofosfamida, vincristina y doxorrubicina para el tratamiento de linfomas no de Hodgkin
JP2011519361A (ja) 2008-04-14 2011-07-07 ハロザイム インコーポレイテッド 修飾されたヒアルロニダーゼおよびヒアルロナン関連疾患および状態の治療における使用
CN102076355B (zh) 2008-04-29 2014-05-07 Abbvie公司 双重可变结构域免疫球蛋白及其用途
ES2558434T3 (es) 2008-11-07 2016-02-04 Amgen Research (Munich) Gmbh Tratamiento de leucemia linfoblástica aguda
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
EP2191842A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
EP2191841A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
EP2191843A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
WO2010083505A1 (en) 2009-01-19 2010-07-22 The Trustees Of The University Of Pennsylvania Method of treating cancer using a survivin inhibitor
CN102459346B (zh) 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
SMT202000092T1 (it) 2009-05-14 2020-05-08 Ambit Biosciences Corp Formulazione essiccata a spruzzo o liofilizzata di ac220
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US9084743B2 (en) 2009-09-17 2015-07-21 Baxter International Inc. Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
KR101808602B1 (ko) 2009-10-07 2017-12-13 마크로제닉스, 인크. 푸코실화 정도의 변경으로 인해 개선된 이펙터 기능을 나타내는 Ｆｃ 영역-함유 폴리펩티드, 그것의 사용 방법
EP2327725A1 (en) 2009-11-26 2011-06-01 InflaRx GmbH Anti-C5a binding moieties with high blocking activity
GB201003701D0 (en) 2010-03-05 2010-04-21 Cilian Ag System for the expression of a protein
WO2011121588A1 (en) 2010-03-29 2011-10-06 Ben Gurion University Of The Negev Research And Development Authority Method and system for detecting and monitoring hematological cancer
CN110066339A (zh) 2010-04-20 2019-07-30 根马布股份公司 含异二聚体抗体fc的蛋白及其制备方法
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
EP2420253A1 (en) 2010-08-20 2012-02-22 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen XV trimerization domain
LT2621531T (lt) 2010-09-27 2017-04-10 Morphosys Ag Anti-cd38 antikūnas ir lenalidomidas arba bortezomibas, skirti išsėtinės mielomos ir nhl (nehodžino limfoma) gydymui
RU2604490C2 (ru) 2010-11-05 2016-12-10 Займворкс Инк. ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ
EP4029881A1 (en) * 2010-11-08 2022-07-20 F. Hoffmann-La Roche AG Subcutaneously administered anti-il-6 receptor antibody
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
UA112170C2 (uk) 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) * 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
CL2013001944A1 (es) 2010-12-30 2014-09-12 Takeda Pharmaceutical Anticuerpo aislado que se une especificamente a cd38 humana y cd38 de cinomolgo; acido nucleico que lo codifica; celula huesped; metodo de produccion; y su uso para tratar una enfermedad autoinmune.
MY161199A (en) 2011-03-23 2017-04-14 Amgen Inc Fused tricyclic dual inhibitors of cdk 4/6 and flt3
EP2561868A1 (en) 2011-08-24 2013-02-27 Anton Bernhard Van Oosten Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
CN104411324A (zh) 2012-04-04 2015-03-11 哈洛齐梅公司 使用抗透明质酸剂和肿瘤靶向紫杉烷的组合疗法
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
HUE036518T2 (hu) 2012-09-25 2018-07-30 Morphosys Ag Kombinációk és alkalmazásaik
DK2914302T3 (en) 2012-11-05 2017-04-10 Morphosys Ag RADIOACTIVALLY MARKED ANTIBODY AND USES OF IT
UA118255C2 (uk) 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
WO2014142220A1 (ja) 2013-03-13 2014-09-18 アステラス製薬株式会社 抗腫瘍剤
US20140271644A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
ES2774976T3 (es) 2013-04-29 2020-07-23 Teva Pharmaceuticals Australia Pty Ltd Anticuerpos anti-CD38 y fusiones con interferón alfa-2b atenuado
US20140356318A1 (en) 2013-05-28 2014-12-04 Israel Barken Adoptive cell therapy with specific regulatory lymphocytes
CN105579058A (zh) 2013-07-15 2016-05-11 小利兰·斯坦福大学托管委员会 Cd38激动剂的医学用途
EP3063173B1 (en) 2013-10-31 2020-07-29 Sanofi Specific anti-cd38 antibodies for treating human cancers
JP2016536361A (ja) 2013-11-06 2016-11-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10106620B2 (en) 2014-06-16 2018-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Blocking CD38 using anti-CD38 F(ab′)2 to protect NK cells
WO2015195555A1 (en) 2014-06-16 2015-12-23 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
MY192918A (en) 2014-09-09 2022-09-15 Janssen Biotech Inc Combination therapies with anti-cd38 antibodies
EP3227338A4 (en) 2014-12-04 2018-05-16 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of acute myeloid leukemia
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
MY192978A (en) 2015-06-22 2022-09-20 Janssen Biotech Inc Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
HUE066300T2 (hu) 2015-06-24 2024-07-28 Janssen Biotech Inc Immunmoduláció és szolid tumorok kezelése CD38-hoz specifikusan kötõdõ antitestekkel
PL3827845T3 (pl) 2015-11-03 2022-07-11 Janssen Biotech, Inc. Formulacje podskórne przeciwciał anty-cd38 i ich zastosowania
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
US20170121417A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
US20180117150A1 (en) 2016-11-01 2018-05-03 Janssen Biotech, Inc. Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
CA3079242A1 (en) 2017-10-31 2019-05-09 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma

Also Published As

Publication number Publication date
EA201890093A1 (ru) 2018-05-31
HK1250666A1 (en) 2019-01-11
IL256242B1 (en) 2024-05-01
NI201700167A (es) 2018-08-01
CN107708734B (zh) 2022-01-11
NZ777133A (en) 2025-05-02
MY192978A (en) 2022-09-20
NZ738208A (en) 2024-07-26
UA125115C2 (uk) 2022-01-12
CA2990406A1 (en) 2016-12-29
SV2017005606A (es) 2018-06-26
DOP2018000181A (es) 2019-03-15
JP2018522857A (ja) 2018-08-16
KR102601550B1 (ko) 2023-11-10
US20160367663A1 (en) 2016-12-22
CN107708734A (zh) 2018-02-16
IL256242B2 (en) 2024-09-01
BR112017027724A2 (pt) 2019-01-08
EA036789B1 (ru) 2020-12-22
PH12017502342B1 (en) 2024-01-05
MX391068B (es) 2025-03-21
EP3310386A4 (en) 2019-01-02
ECSP17084270A (es) 2018-02-28
US10668149B2 (en) 2020-06-02
CO2017013331A2 (es) 2018-05-21
EP3310386A1 (en) 2018-04-25
JP6816038B2 (ja) 2021-01-20
GT201700284A (es) 2019-08-26
CR20170587A (es) 2018-04-03
EP3310386B1 (en) 2021-07-21
IL256242A (en) 2018-02-28
HK1250928A1 (zh) 2019-01-18
AU2016282674A1 (en) 2018-01-18
WO2016209921A1 (en) 2016-12-29
PH12017502342A1 (en) 2018-07-02
AU2016282674B2 (en) 2022-01-13
MX2018000265A (es) 2018-05-23
PE20181323A1 (es) 2018-08-14
KR20180015258A (ko) 2018-02-12
ES2890783T3 (es) 2022-01-24
MA46315A (fr) 2019-08-07
ZA201800403B (en) 2021-07-28

Similar Documents

Publication Publication Date Title
CL2017003255A1 (es) Terapias de combinación para males hematologicos con anticuerpos anti-cd38 e inhibidores de survivin.
CL2017002909A1 (es) Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras malignidades hematologicas cd38-positiva.
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
CL2017001515A1 (es) Receptores de antígeno químericos bcma
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
MX2022005211A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
ECSP17021175A (es) Terapias de combinación con anticuerpos anti-cd38
EA201691974A1 (ru) Антитела против ox40 и способы их применения
EA201691610A8 (ru) Анти-jagged1 антитела и способы применения
CL2017001408A1 (es) Anticuerpos anti-cd79b y métodos de uso
EA201591285A1 (ru) Иммунотерапия тау
CL2017001393S1 (es) Automovil
CL2017001185S1 (es) Automovil
CL2017001361A1 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
CL2016001871A1 (es) Anticuerpos humanos para pd-1
CL2017001046A1 (es) Inhibidoes del bromodominio
EA201691214A1 (ru) Антитела к cd33 и иммуноконъюгаты
BR112017004802A2 (pt) anticorpos anti-cll-1 e imunoconjugados
BR112016007891A2 (pt) uso de inibidores de bromodomínio cbp/ep300 para imunoterapia do câncer
EA201691367A1 (ru) Кристаллические формы дималеата афатиниба
EA201690383A1 (ru) НОВЫЕ АНТИТЕЛА К FC-γ-РЕЦЕПТОРУ IIB И ИХ ПРИМЕНЕНИЯ
MX2017000526A (es) Formulaciones de anticuerpos cristalinos.
CO2018010286A2 (es) Método para la purificación de proteínas
EA201790428A1 (ru) Синтез энт-прогестерона и его промежуточных соединений
AR106533A1 (es) Combinación de terapias para enfermedades hemo con anticuerpos anti-cd38 e inhibidores de survivina